-
International HIV vaccine trials underway in resource-poor settings provide good examples of how clinical research (CR) can be done in both ethical and culturally-sensitive ways despite a wide variety of obstacles.
-
Many clinical research institutions have limited resources for internal audits or quality improvement (QI) checks, so the key is to create proactive tools and policies to improve overall site regulatory compliance.
-
While ClinicalTrials.gov offers the public searchable information about clinical trials that might interest them, another research website offers investigators the potential of reaching their trial's enrollment goals without having to run an advertisement.
-
Clinical trial sites can improve their clinical trial (CT) negotiation processes and reduce misunderstandings with sponsors and clinical research organizations by being clear about objectives and desires.
-
Collecting timely payments from sponsors is a common issue for clinical trial sites. Assigning payments to the correct budget also can be a problem. Mistakes in these areas can lead to cash-flow difficulties.
-
One of the technological advances resulting from the National Institutes of Health's (NIH's) Clinical Translational and Science Awards (CTSA) project is a stream-lined, flexible, and interoperable data capture system called the REDCap (Research Electronic Data Capture).
-
When the National Institutes of Health (NIH) of Bethesda, MD, rolled out its Roadmap for Medical Research about eight years ago, the chief goals were to speed up the lab-to-bedside research process, strengthen areas in clinical research, and develop regional translational resource centers.
-
-
Using a quality improvement (QI) process, ICU delirium, physical rehabilitation, and functional mobility were significantly improved and associated with a decreased length of stay.
-
Outpatients with uncomplicated seasonal influenza were treated with single doses of IV peramivir 300 mg/kg, 600 mg/kg, or placebo. Peramivir significantly reduced the time to alleviation of symptoms at both doses compared with placebo. Peramivir was well-tolerated, and side effects were comparable to placebo.